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Abstract
Purpose Because the cytotoxic potential of hydrophilic
drugs like bleomycin (BLM) is restricted by its low
membrane permeability, the application of low-intensity
ultrasound (US) on growing tumor cells enhances intra-
cellular delivery of BLM after intratumoral administration,
thereby potentiating its cytotoxicity. In the present study,
the in vivo cell membrane permeability enhancement with
US (1 MHz, 2, 5, and 10 min, ISPTA = 2 W/cm
2) is com-
pared with the murine model of breast adenocarcinoma in
BALB/c mice.
Methods Tumor induction was performed through a
homograft surgery procedure. Mice were anesthetized
before putting them in sonication situations. Sonications
were done in an aquarium. Seven groups of the tumor-
bearing mice, each consisting of eight mice, were sonicated
without or after intratumoral injection of 0.1 ml BLM at
different exposure times. The tumor volume was evaluated
to assess the growth process by use of a digital caliper.
Results The results show that the BLM control group has
a significant difference with BLM plus 10 min US on day 2
(p\ 0.05). There is a significant difference between 2- and
10-min sonication on days 8 and 10 also. The difference
between the Only US group and the other groups except
Sham US was significant too (p\ 0.05). Significant dif-
ferences were seen only between the BLM plus US groups
with Sham US and Only US control groups.
Conclusion It has been concluded that for significant
permeabilization of the cell membrane, sonication time for
more than 10 min is required. Significant difference
between the Only US and other groups indicates that US
has a promoting effect on cell division procedure, in spite
of the no-carcinogen effect of the US.
Keywords Sonochemotherapy  Bleomycin  Breast
adenocarcinoma  In vivo
Scopo Poiche´ il potenziale citotossico di farmaci idrofili
come la bleomicina (BLM) e` limitato dalla scarsa per-
meabilita` della membrana cellulare, l’applicazione di ul-
trasuoni a bassa intensita` (US) sulle cellule tumorali in
crescita aumenta la diffusione intracellulare di BLM, dopo
somministrazione intratumorale, potenziandone cosı` la
citotossicita`. Nel presente studio, il miglioramento in vivo
della permeabilita` delle membrane trattate con gli US
(1 MHz, 2, 5, and 10 min, ISPTA = 2 W/cm
2) e` stato
confrontato con il modello di adenocarcinoma mammario
in topi BALB/c.
Metodi L’ induzione del tumore e` stata effettuata at-
traverso una procedura di chirurgia omografa. I topi sono
stati anestetizzati prima di essere sottoposti ad ecografia,
effettuata in acqua. Sette gruppi di topi portatori di tumore,
ciascuno composto da otto topi, dopo o in assenza di ini-
ezione intratumorale di 0.1 ml BLM, sono stati sottoposti
ad ultrasuoni con diversi tempi di esposizione. Il volume di
crescita del tumore e` stato valutato mediante l’uso di un
calibro digitale.
Risultati I risultati mostrano che il gruppo di controllo
BLM ha una differenza significativa con il gruppo BLM
dopo 10 min US al secondo giorno (p\ 0,05). Vi e` una
differenza significativa tra 2 e 10 minuti di esposizione agli
ultrasuoni anche all’ottavo e decimo giorno. La differenza
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tra il gruppo sottoposto agli utrasuoni e gli altri gruppi e`
molto significativa (p\ 0.05). Differenze significative
sono state osservate solo tra i gruppi BLM sottoposti ad
ultrasuoni, non sottoposti ad ultrasuoni e solo ad ultrasuoni.
Conclusione Si e` concluso che per una significativa per-
meabilizzazione della membrana cellulare, questa debba
essere sottoposta agli ultrasuoni per piu` di 10 minuti.
Differenza significativa tra i soli gruppi statunitensi e di
altri indica che gli Stati Uniti ha un effetto sulla pro-
mozione procedura di divisione cellulare, nonostante
l’effetto no-cancerogeno degli Stati Uniti.
Introduction
Cancer remains a leading cause of morbidity and mortality
despite knowledge of its molecular basis, detection, and
treatment. One of the most common cancers is breast
adenocarcinoma. Many cancers evade the curative
endeavors of conventional therapies like surgical resection,
chemotherapy, and radiotherapy. Because of the involve-
ment of a vital vein or nerve, many are inoperable, meta-
static at first presentation, fail to respond to treatment, or
following successful initial treatment may subsequently
recur [1–4]. Because of the side effects of anesthesia,
usually old patients are not candidates for surgery.
Radiotherapy has abundant side effects, and X and c
radiations are carcinogen factors.
Chemotherapy also has very bad side effects. So usually, a
combined treatment is used to improve the efficiency of each
one of the treatments. Therefore, the development of alter-
native therapies for such cancers is clearly an imperative.
One of the revolutionary treatment methods for cancer is the
combination of physical modalities and routine treatments.
Physical modalities such as ultrasound (US) waves,
electric field, etc., with different specifications have been
used in this relation [5–9]. The combination of such
physical modalities with routine treatment methods often
leads to a reduction of the chemical drug dose and a
decrease or total deletion of many side effects of these
drugs and increases the efficiency of the treatment on the
tumor and also the preservation of normal tissues [10].
One of the first physical modalities that were used was
US waves. US waves with different intensities and fre-
quencies have different biological effects. The effect of US
on biological tissues depends on some exposure factors—
such as frequency, intensity, power, exposure time, mode
of irradiation… [9, 11, 12]. US has a unique advantage
over other physical modalities that can penetrate through
body tissues; it is focused on small areas and shows a
completely targeted performance.
There are two major effects related to US waves: heat
production and cavitation. The range of diagnostic US
intensities is between 0 and 2 W/cm2, and the frequencies
are from 1 to 20 MHz; this range is in the low-level
intensity US.
Until now, no investigation shows the adverse biological
effect of low-level intensity US, which is used routinely in
clinics. In this range of US waves, transient cavitation
process is improbable. However, the reflection of US
waves from the opposite side wall of the aquarium may
lead to the production of standing waves and subsequent
transient cavitation. To avoid the occurrence of this phe-
nomenon in the aquarium, using a US absorber, we opted
to use the progressive wave mode [13–16]. While using
US, there are two main categories of heat production:
hyperthermia and high-intensity focused ultrasound
(HIFU). HIFU needs intensities at the kW range, so it was
not used in our trial. Temperature rising in low-level
intensities is less than 10 C, but it is sufficient for
occurring biological effects [17].
Bleomycin prescription is one of the routine treatment
protocols for many cancers [18]. Cell death due to bleo-
mycin happens in one of two ways [19]. If only a few
thousand bleomycin molecules are present in the cell, the
cell is arrested in the G2–M phase, becomes enlarged, and
polynuclei and micronuclei are observed [19, 20]. The cell
then dies in a slow process lasting about three doubling
times [20]. If, however, the cell contains several million
bleomycin molecules, it will be killed within a few minutes
through pseudoapoptosis, where bleomycin short circuits
the apoptotic pathway by creating the characteristic DNA
fragmentation. This is followed by cell shrinkage, mem-
brane blebbing, and chromatin condensation [18, 20, 21].
Bleomycin is an extremely toxic agent once inside the
cell [22], but this very high intrinsic cytotoxicity is
restricted by the inability of bleomycin to freely diffuse
through the plasma membrane [19, 20, 23]. Thus, it has
been shown in vitro that less than 0.1 % of the bleomycin
added to the extracellular medium becomes associated with
the cells [24]. Therefore, it is an essential need to improve
the diffusion of bleomycin through the plasma membrane
to decrease the dose of the drug and subsequently the side
effects on normal tissues.
In the present study, the in vivo cell membrane perme-
ability enhancement with US at 2, 5, and 10 min exposure
times by low-level intensity (ISPTA = 2 W/cm
2) was




The photo of the experimental setup is shown in Fig. 1.
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The US source was a 1 MHz US (Sonopulse 492, Enrof-
Nonius Co., The Netherlands) with a PZT transducer probe
(30-mm diameter and an area of 5 cm2) with pulsed mode
and duty cycle of 80 %. Acoustic calibration for power and
intensity of this device was carried out in degassed water
using a US power meter balance (UPM-DT-10, Netech,
Hicksville, NY, USA, ±1 mW). The intensity quoted was
spatial average, temporal average (ISATA) of 2 W/cm
2.
For exposure under controlled conditions, the apparatus
used was a cubical tank with dimensions 25 9 25 9
20 cm3 constructed of Plexiglas and filled with degassed
water. To eliminate the production of air bubbles between
the probe and the tumor, a small amount of detergent was
added to the tank. To perform the experiments under pro-
gressive wave conditions and to eliminate acoustic reflec-
tion and production of standing waves by the opposite wall
of the tank, in front of the probe, a piece of an US absorber
was attached to it.
The temperature of the water in the tank during tumor
sonication was 35–38 C. To control the temperature of the
water in the tank, an aquarium heater equipped with a ther-
mostatic control was used at all times, and the temperature
was monitored during all experiments, with a digital ther-
mometer. The probe held fixed in the tank through a circular
hole at a distance from the corner of the tank makes it pos-
sible for the sonication of themouse in the cage. The tumor is
placed in the closest location to the probe surface.
The holder system for the tumor-bearing mouse was a
cage constructed of fine polystyrene fiber suspended in the
water in front of the probe. This system had the potential
for movement in three directions and thus was completely
adjustable for the manipulation of the tumor in front of the
probe surface.
Experimental procedure
Fifty-six healthy female BALB/c mice (6–8 weeks of age)
were purchased from the Pasteur Institute (Tehran, Iran).
They were kept at 22 C with a natural day/night cycle for
10 days for adaptation. Spontaneous mouse mammary
tumor (i.e., an invasive ductal carcinoma) was transplanted
by implanting a 4-mm3 fragment into the right flank of the
anesthetized mice through homograft surgery. Approxi-
mately 2 weeks after tumor transplantation, when the
largest tumor diameter exceeded 5 mm (measured by a
digital caliper), the animals were randomly divided into
seven groups (eight animals for control groups and for each
of the experimental groups).
Drug preparation
One ml injectable saline was added to the bleomycin
(BLM) vial, which contains 15 mg of crystalline powder
BLM. This solution contained 25 U of drug. Thus, in each
0.1 ml of it, 2.5 U of BLM was present. Depending on
tumor size, the appropriate dose of BLM was injected
directly into the tumor. The injection was performed in two
steps at two opposite points of the tumor. It was done for
better drug spreading throughout the tumor volume.
For the anesthesia, we used a solution that contains 4 ml
saline and 0.5 ml of etamine (10 %) (Alfasan Woerden,
Netherlands) and 0.5 ml of xylazine (2 %) (Alfasan
Woerden, Netherlands).
Experimental groups
Seven experimental groups were present in this research.
• Bleomycin control group (BLM Cont.): In this group,
only 0.1 ml of the BLM solution was injected into the
tumor. No irradiation was used. The BLM content in
the injected solution depends on the tumor size and was
based on the standards in Table 1 [20].
• Sham control group (Sham Cont.): 0.1 ml of distilled
water injected into the tumor.
• BLM plus 2-min US irradiation group: The mouse was
anesthetized by an IP injection of the 0.01 ml anesthe-
sia solution for each gram of its body weight. Then,
0.1 ml of the BLM solution was injected into the tumor.
After 3 min, the tumor irradiated with pulsed US waves
at 2 W/cm2, with 80 % duty factor for 2 min at the
prepared setup.
• BLM plus 5-min US irradiation group: The mouse was
anesthetized by an IP injection of the 0.01 ml anesthe-
sia solution for each gram of its body weight. Then,
0.1 ml of the BLM solution was injected into the tumor,
and after 3 min, the tumor irradiated with pulsed US
Fig. 1 Mouse in the sonication setup
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waves at 2 W/cm2, with 80 % DF for 5 min at the
prepared setup.
• BLM plus 10-min US irradiation group: The mouse was
anesthetized by an IP injection of the 0.01 ml anesthe-
sia solution for each gram of its body weight. Then,
0.1 ml of the BLM solution was injected into the tumor,
and after 3 min, the tumor irradiated with US waves at
2 W/cm2, with 80 % DF for 10 min at the prepared
setup.
• Sham US group: The mouse was anesthetized and put
in the same situation as the irradiation groups at the
setup, but no irradiation was applied to it. No BLM was
used.
• Only US group: The mouse was anesthetized by an IP
injection of the 0.01 ml anesthesia solution for each
gram of its body weight; no BLM injection was used,
and after 3 min, the tumor irradiated with pulsed US
waves at 2 W/cm2, with 80 % DF for 5 min at the
prepared setup.
The tumor diameters were measured every 48 h using a
0.02 mm digital caliper, and the tumor volume was cal-
culated by standard formula. The formula most often used
to measure the tumor volume is V = ab2p/6, in which a is
the longest diameter and b is the next longest diameter
perpendicular to a [21].
Using Microsoft Excel, the data were processed and the
graph of tumor growth delineated and rendered. Analyzing
the data was performed using SPSS 18 software.
Results
The growth curve of the tumor in the experimental groups,
between the treatment day and the 22nd day, is shown in
Fig. 2.
Analyzing the data with SPSS showed that there is no
difference between the experimental groups at treatment
day (p\ 0.05).
The growth of tumor in the Sham control group fromday 2
until day 6 was significantly more than other groups except
Sham US; nevertheless, tumor growth was significantly less
than theOnlyUSgroup.On days 8–14, its differencewith the
BLM plus 2-min US group became insignificant. During
days 10–12, the growth of tumor in the Sham control was
significantly more than the BLM plus 10-min US and less
than the Only US group. During days 16–18, the growth of
tumor in the Sham control was significantly more than the
BLM plus 5- or 10-min US and less than the Only US group.
On day 20, the growth of tumor in the Sham control was
significantly more than the BLM plus 10-min US and less
than the Sham US and Only US groups. On day 22, the
growth of tumor in the Sham control was significantly more
than the BLM plus 5- or 10-min US and less than the Sham
US and Only US groups (p\ 0.05, SEM = 364.83013).
The BLM control group on day 2 shows significant
difference with all groups except the BLM plus 2- or 5-min
US groups. On days 4, 6, and 8, the growth of tumor in the
BLM control group was significantly more than all the
groups except BLM plus US groups. On all other days, it
does not have a significant difference compared with other
groups except the Sham US and Only US groups, where its
growth was less than them (p\ 0.05, SEM = 270.906).
The growth of tumor in the BLM plus US-treated groups
was significantly less than in the Sham groups and the Only
US group on days 2, 4, and 6.
On days 8–10, the BLM plus 2-min US shows signifi-
cantly more growth of tumor compared with the BLM plus
10-min US and less than the Sham US and Only US. In
addition, the growth of tumor in the BLM plus 5- or 10-min
US on day 8 was significantly less than the Sham Cont.,
Sham US, and Only US groups.
On day 10, the growth of tumor in the BLM plus 5-min
US was significantly less than the Sham US and Only US,
whereas the tumor volume in the BLM plus 10-min US was
significantly less than the Sham control group and also the
two mentioned control groups.








Between 100 and 150 0.75 0.45
Between 150 and 200 1.00 0.61
Between 200 and 250 1.50 0.91
Between 250 and 300 2.00 1.21
[300 2.50 1.51
a One unit (U) contains 0.56–0.66 mg of BLM
Fig. 2 Tumor growth curve for seven groups of Balb/C mice (eight
mice per every group) bearing tumors of murine breast adenocarci-
noma: filled circle Sham US, vertical line Only US, filled triangle
Sham Control, filled square BLM control, filled triangle BLM ?2
min US, multi symbol BLM ?5 min US, asterisk BLM ?10 min US
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On day 12, the growth of tumor in the BLM plus 2- or
5-min US was significantly less than the Sham US and
Only US groups, while the growth of tumor in the BLM
plus 10-min US shows significant less volume compared
with the Sham control and also the two other mentioned
control groups.
On days 14 and 16, when the growth of tumor in the
BLM plus 2-min US was significantly less than the Sham
US and Only US groups, the growth of tumor in the BLM
plus 5- or 10-min US was also less than in the Sham control
group.
On day 18, the growth of tumor in the BLM plus 2-min
US was significantly more than the BLM plus 10-min US
and less than the Sham US and Only US groups. Other
results are the same as on day 16.
The results on days 20 and 22 were the same as on days
14 and 16.
Discussion
The effectiveness of chemotherapeutical drugs is dictated
by the rate and extent the drug penetrates tissues and cells
associated with the cancer, being limited by the side effects
the drug exerts on tissues and cells not associated with the
cancer. In this regard, the tumor blood vessel wall and the
cancer cell membrane create physiological barriers for
anticancer drugs.
The combination of US and chemotherapeutic drugs is
currently exploited to enhance cancerous cells membrane
permeabilization and uptake of the drug by the target cells
[25–30]. Because US can be easily directed to specific sites
or organs, it may be possible to increase the uptake of
drugs and genetic material locally and selectively for the
effective delivery of a drug into the cytosol [31].
The delivery of impermeable compounds like BLM by
use of US into the cytosol has been demonstrated both in
the in vitro [29, 30] and in vivo studies [32, 33]. The
phenomenon of reversibly increasing the permeability of
biological membranes is called sonoporation. The physical
mechanisms by which this occurs have yet to be elucidated.
However, mechanisms due to bubble disruption (formation
of microjets and shock waves) and stable bubble oscillation
(acoustic microstreaming) in ultrasonic fields are almost
certainly implicated [34, 35]. This work investigates the
permeabilization of murine breast adenocarcinoma cells to
BLM in an in vivo experiment by use of US in three dif-
ferent exposure times.
The biophysical basis of the uptake of impermeable
macromolecules, under our conditions, seems to be the
formation of transient pores on the surface of the cell
membrane [36].
There are two types of cavitation due to the use of US:
transient cavitation and inertia cavitation [37]. The occur-
rence of transient cavitation has threshold exposure
parameters that are higher than the utilizing exposure
parameters in this trial [13–16]. Nevertheless, the occur-
rence of inertia cavitation is possible. Cell membrane
permeabilization and enhancing the efficiency of the che-
motherapy by use of low-level US by means of inertia
cavitation is an established trial [7, 9]. Inertia cavitation
has two separate effects:
(a) Microstreaming, which has the main role in cell
membrane permeabilization.
(b) Heat production.
By reviewing the results, it can be understood that both
of these phenomena play their roles in the trial.
SPSS results show that the growth of the tumor in the
BLM plus US groups decreases compared with the Sham
groups. However, the growth of the tumor in the Only US
group increases compared with the other groups. This fact
shows that BLM plus US reduces the volume of the tumor,
but at the absence of BLM, the volume of the tumor will
increase.
It can be because of the inertia cavitation action that
enhances permeabilization of the cell membrane to BLM.
Vice versa, in the absence of BLM, heat production leads
to temperature enhancement, and in turn, temperature
enhancement leads to vasodilatation and increased blood
perfusion and better nutrition and oxygenation of the tumor
cells. Thus, cell division exceeds and tumor volume
increases faster compared to an unexposed tumor.
The insignificance of the difference of the BLM control
group versus the BLM plus 2- and 5-min groups reveals the
ineffectiveness of these US combination treatments. Nev-
ertheless, the significant difference of the BLM control
group vs. the BLM plus 10-min US group on day 2 shows a
threshold time in this issue. It has been shown that US
waves can unsettle the cell membrane structure [38, 39]. It
also seems that low-level US is effective in making cell
membrane permeabilized to BLM, but to become signifi-
cant vs. the BLM control group on more days, the irradi-
ation time must be longer than 10 min.
Nevertheless, both the BLM control group and the plus
10 min have a significant negative difference compared
with the Sham US and Only US groups.
In this case, it seems the presence of physiological and
psychological stresses in the Sham US and Only US groups
and, as mentioned before, the US itself is a promoting
factor and can lead to making significant negative differ-
ences for the BLM control group versus these two groups.
As shown in Fig. 2, after the eighth day, the graph
begins to rise, and it seems the repair process of the pores is
J Ultrasound (2015) 18:165–171 169
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going to become complete. The return to the initial situa-
tion can gradually happen even longer.
The 10-min irradiation is outstanding in revealing
treatment effects. Its difference with the BLM control
group on the second day is significant at p = 0.045
(SEM = 10.32842). It seems that this treatment time is the
most effective one to make turbulence in the cell mem-
brane structure and establish more pores in the cell mem-
brane. These events affect the membrane so efficiently, and
therefore, the number of drug molecules that can enter the
cell is more than other exposure times. To make a pore in
the cell membrane, a completely defined deal of energy is
required, so with increasing irradiation time, more energy
will transfer to the cell membrane, and it seems we become
closer to that defined energy. Nevertheless, there is a limit
in making pores in the cell membrane. Beyond this limit,
the pores will be irreversible, and the cell may erupt. It
makes a perspective for tumor treatment without any drug
and side effects by localized US.
However, it is expected that by increasing the exposure
time beyond 10 min, the difference between the BLM
control group and the BLM ? X min becomes significant
at p\ 0.05 on more days.
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